Categories
Change Password!
Reset Password!
Self-reported and self-assessed survey can be used to evaluate the
effectiveness of pamidronate for chronic recurrent
multifocal osteomyelitis.
An observational research issued in Rheumatology International described the gradual action of pamidronate with different symptoms alleviation between the sexes in children with NSAIDs-refractory chronic recurrent multifocal osteomyelitis (CRMO). This conclusion was based on self-made questionnaires comprising of questions related to symptoms improvement, frequency of adverse drug reactions (ADRs) and extent of severity and daily activities self-reliance with the use of pamidronate therapy for NSAIDs-refractory CRMO.
The study authors- Bartłomiej Juszczak and Jerzy Sułko evaluated the online surveys with finished answers. A total of 61 pediatric patients with NSAIDs-refractory CRMO were considered. Fourty-two complete answers (9 males and 33 females) were collected and examined. These patients were administered with a minimum of 1 set of pamidronate intravenously dosed at 1 mg per kg daily for 3 days.
As found, the decrease of pain intensity was noteworthy following 2.5 series of pamidronate, and total pain relief following 5.9 series on an average. The number of adverse drug reaction events reported was 105. During the therapy course, 1 patient developed drug-dependent renal insufficiency. About half of the studied population was more enthusiastic to participate in social life after the first drug infusion.
Almost all the surveyed commonly agreed to suggest Pamidronate and
considered it to be effective at the end of the therapy for NSAIDs-refractory
CRMO. The use of pamidronate can encourage extensive number of ADRs (2.5 per
patient). Only 7% patients were free from any ADRs. The study authors call for
more precise research on the effect of pamidronate on routine activities.
Rheumatology International
Patient-reported effectiveness and safety of Pamidronate in NSAIDs-refractory chronic recurrent multifocal osteomyelitis in children
Bartłomiej Juszczak et al.
Comments (0)